NCT06501664View on ClinicalTrials.gov

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
Esophageal Cancer
Interventions
DRUG

liposomal irinotecan

Liposomal irinotecan 70 mg/m²

DRUG

5-FU

5-FU 400 mg/m² bolus then 2400 mg/m2 over 46 h

DRUG

LV

LV 400 mg/m²

DRUG

Irinotecan

Irinotecan 180 mg/m²

All Listed Sponsors
lead

Rui-hua Xu, MD, PhD

OTHER